Brief: Ose Immunotherapeutics: European Patent Notice Of Allowance For FR104
12/10/2020 17:03
Oct 12 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS RECEIVES EUROPEAN PATENT NOTICE OF ALLOWANCE FOR FIRST-IN-CLASS
CD28-ANTAGONIST IMMUNOTHERAPY FR104
Source text for Eikon: ID:nBw3F3bXxa
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO